| Literature DB >> 31144772 |
Amy Barone1, Denise Casey1, Amy E McKee2, Gregory Reaman2.
Abstract
It is well appreciated that the number of anticancer drugs approved for use in children is a fraction of the number approved for use in cancers that occur in adults. We address this fact by summarizing the relevant U.S. legislation that provides the framework for the evaluation and approval of drugs used to treat children with cancer. In total, the Food and Drug Administration (FDA) has approved 38 new drug applications for pediatric oncology indications, 12 of which were new molecular entities. FDA continues to collaborate with multistakeholders regarding the development of products intended for pediatric cancer and encourages the submission of marketing applications. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.Entities:
Keywords: FDA; cancer; children; drug approval
Year: 2019 PMID: 31144772 DOI: 10.1002/pbc.27809
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167